David E. Fisher Receives 1998 Gertrude B. Elion Cancer Research Award

Publication
Article
OncologyONCOLOGY Vol 12 No 5
Volume 12
Issue 5

David E. Fisher, MD, PhD is the recipient of the sixth Gertrude B. Elion Cancer Research Award, sponsored by the American Association for Cancer Research (AACR). Since 1993, the award has been presented annually to one nontenured

David E. Fisher, MD, PhD is the recipient of the sixth Gertrude B. Elion Cancer Research Award, sponsored by the American Association for Cancer Research (AACR). Since 1993, the award has been presented annually to one nontenured scientist, at the assistant professor level, who is involved in basic or clinical research on the causes, prevention, or treatment of cancer.

Dr. Fisher was selected as the 1998 recipient of the Elion Award on the basis of his research proposal entitled, “Microphthalmia and p16: Critical Regulators of Melanocyte Growth and Survival.” This proposal aims to: (1) explore the mechanisms by which the cell cycle in melanoma cells modulates microphthalmia (Mi) activity; and (2) identify Mi “target genes” and thereby determine when Mi is involved in cell differentiation and when it regulates proliferation or survival. To the extent that Mi is involved in cell survival, it could prove to be an attractive target for therapeutic intervention.

Dr. Fisher has already attained an international reputation for his work in two important areas of cancer research: the molecular events regulating apoptosis, or programmed cell death, and the activity of Mi, which has a major role in the production of skin pigmentation. He is currently assistant professor at the Children’s Hospital/Dana-Farber Cancer Institute and Harvard Medical School in Boston, Massachusetts. Dr. Fisher earned his doctorate in immunology and cell biology at Rockefeller University and his medical degree at Cornell Medical College. He completed clinical training in internal medicine at Massachusetts General Hospital and in hematology/oncology at Dana-Farber Cancer Institute and The Children’s Hospital. He then performed research as a postdoctoral fellow with Nobel Laureate Phillip A. Sharp, phd, at the Massachusetts Institute of Technology. Dr. Fisher has an extensive record of publications on molecular biology and genetics, particularly with regard to cell growth and differentiation.

Recent Videos
Breast cancer care providers make it a goal to manage the adverse effects that patients with breast cancer experience to minimize the burden of treatment.
Social workers and case managers may have access to institutional- or hospital-level grants that can reduce financial toxicity for patients undergoing cancer therapy.
Genetic backgrounds and ancestry may hold clues for better understanding pancreatic cancer, which may subsequently mitigate different disparities.
Factors like genetic mutations and smoking may represent red flags in pancreatic cancer detection, said Jose G. Trevino, II, MD, FACS.
Thomas Hope, MD, believes that an NRC initiative to update infiltration guidelines may organically address concerns that H.R. 2541 outlines.
Insurance and distance to a tertiary cancer center were 2 barriers to receiving high-quality breast cancer care, according to Rachel Greenup, MD, MPH.
4 experts are featured in this series.
4 experts are featured in this series.
Thomas Hope, MD, had not observed an adverse effect attributable to an infiltration across more than a decade of administering nuclear agents at UCSF.
Numerous clinical trials vindicating the addition of immunotherapy to first-line chemotherapy in SCLC have emerged over the last several years.
Related Content